Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Eicosapentaenoic acid** is a C20 polyunsaturated omega-3 fatty acid found in fish oils and other marine lipid sources. In biological systems, the naturally occurring all-cis form is incorporated into membrane phospholipids and serves as a precursor of omega-3-derived eicosanoids, including prostaglandin-3 and thromboxane-3 series mediators; it can also alter arachidonic-acid eicosanoid metabolism. The unqualified chemical name is stereochemically nonspecific, although nutritional and clinical literature commonly uses it to refer to naturally occurring all-cis EPA. It has been studied as an oral intervention, including in colorectal cancer liver metastases. It must not be conflated with **icosapent ethyl**, the distinct ethyl-ester pharmaceutical active ingredient in Vascepa. ([pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/compound/Icosapent))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eicosapentaenoic acid.